PCRX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Pacira Biosciences Inc (PCRX). It details various technical indicators, including moving averages, oscillators like RSI and MACD, and identifies key support and resistance levels. The overall technical consensus for PCRX is a "Strong Sell" based on multiple indicators.
PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison
Pacira Biosciences Inc (PCRX) generates the majority of its revenue from EXPAREL, which accounts for 78.6% of total sales. The company maintains a strong gross margin of 72.26%, with an operating margin of 1.93% and a net margin of 0.83%. PCRX competes with companies like CMPX and CTMX, and its financial performance is benchmarked against these industry peers.
(PCRX) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis for Pacira Biosciences Inc. (NASDAQ: PCRX), highlighting stable neutral readings in shorter horizons that could suggest an easing of a long-term weak bias. It outlines an exceptional risk-reward setup targeting a 12.0% gain versus a 0.3% risk. The analysis also details institutional trading strategies for different risk profiles, including long, breakout, and short positions, alongside multi-timeframe signal analysis.
Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence
Pacira BioSciences Inc. (NASDAQ: PCRX) presented data from its IGOR registry at the 2026 AAOS Annual Meeting, showing that Exparel improved pain outcomes and reduced opioid use. The company also highlighted iovera's long-lasting pain relief and functional improvement. These findings, along with recent survey results on the NOPAIN Act, strengthen Pacira's position in non-opioid pain management solutions.
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
Pacira BioSciences announced findings from two real-world studies demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with reduced total cost of care in total knee arthroplasty (TKA) and spinal fusion procedures. These studies highlight lower healthcare resource utilization and shorter hospital stays when EXPAREL is used compared to standard of care options. The data will be presented at the Orthopaedic Research Society 2026 Annual Meeting, reinforcing EXPAREL's role in cost-effective non-opioid pain management.
Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
Pacira BioSciences announced findings from two real-world studies demonstrating the economic benefits of EXPAREL (bupivacaine liposome injectable suspension) in orthopedic procedures, including total knee arthroplasty (TKA) and spinal fusion. The studies show EXPAREL is associated with lower total cost of care and reduced healthcare resource utilization compared to ropivacaine or standard of care options. These data will be presented at the Orthopaedic Research Society 2026 Annual Meeting.
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
Pacira BioSciences announced findings from two real-world studies demonstrating that its non-opioid pain therapy, EXPAREL (bupivacaine liposome injectable suspension), is associated with a reduced total cost of care in orthopedic procedures. The studies, which focused on total knee arthroplasty and spinal fusion, showed lower costs and decreased healthcare resource utilization compared to ropivacaine or other standard-of-care options. These findings will be presented at the Orthopaedic Research Society 2026 Annual Meeting, emphasizing EXPAREL's role in improving patient outcomes and alleviating economic burdens.
Study data linked EXPAREL to lower knee and spine surgery costs
Pacira BioSciences presented real-world study data at the Orthopaedic Research Society 2026 Annual Meeting, indicating that its pain therapy EXPAREL is associated with lower total costs of care for patients undergoing total knee arthroplasty (TKA) and spinal fusion. The studies showed reduced 30-day total costs, decreased resource utilization, and shorter hospital stays for EXPAREL recipients compared to those receiving ropivacaine or other non-liposomal bupivacaine analgesia. These findings reinforce EXPAREL's economic value within multimodal pain management strategies.
Vanguard amends Schedule 13G/A after internal realignment (PCRX)
Vanguard has filed an amended Schedule 13G/A for Pacira BioSciences (PCRX), reporting zero beneficial ownership of the company's common stock. This change, effective January 12, 2026, is due to an internal realignment within The Vanguard Group, which resulted in disaggregated reporting by its subsidiaries. The filing indicates that these subsidiaries will now report beneficial ownership separately.
Pacira BioSciences (NASDAQ:PCRX) Price Target Cut to $25.00 by Analysts at Barclays
Barclays has cut its price target for Pacira BioSciences (NASDAQ:PCRX) from $27.00 to $25.00, maintaining an "equal weight" rating, citing the company's recent earnings and revenue miss. Despite this, the stock holds a consensus "Hold" rating among analysts with an average price target of $30.25, indicating varied opinions on its future performance. The company's shares opened at $23.43, with a market capitalization of $948.68 million, after reporting lower-than-expected EPS and revenue for the last quarter.
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Several prominent stocks, including Absci (ABSI), DigitalOcean (DOCN), Intrepid Potash (IPI), and Pacira Biosciences (PCRX), experienced declines in pre-market trading on Wednesday. Absci's shares fell significantly after reporting worse-than-expected quarterly sales, while DigitalOcean announced a $700 million offering affecting its stock. Other companies like Intrepid Potash, Pacira Biosciences, Velo3D, Sasol, CF Industries Holdings, and Venture Global also saw their stock prices move lower.
PCRX: Barclays Lowers Price Target to $25, Maintains Equal-Weigh
Barclays has reduced its price target for Pacira BioSciences (PCRX) from $27.00 to $25.00, while maintaining an Equal-Weight rating. This adjustment reflects Barclays' latest analysis and market trends, prompting investors to consider these changes alongside historical ratings. Pacira BioSciences specializes in non-opioid pain management and regenerative health solutions, with an average target price among analysts of $32.13, indicating a potential upside from its current price.
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings
Pacira Biosciences is facing a board challenge from activist investor Paramount BioCapital, which owns a 2.5% stake. Paramount is criticizing Pacira's CEO David Stack's "excessive" compensation, comparing it unfavorably to other pharmaceutical CEOs, and highlighting missed adjusted earnings, revenue targets, and a significant drop in stock price. The activist is pushing for changes to the board and management to improve performance and shareholder value.
(PCRX) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses Pacira Biosciences Inc. (NASDAQ: PCRX) through the lens of quantitative research. It highlights a near-term weak sentiment that may signal a resumption of long-term weakness and identifies resistance being tested. The analysis includes various trading strategies with defined entry zones, targets, and stop losses, generated by AI models for different risk profiles.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages
Pacira BioSciences (NASDAQ:PCRX) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $30.75 from six analysts. This recommendation comes despite the company missing its recent quarterly earnings and revenue estimates. Insider selling and high institutional ownership are also noted in the report.
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock
Jonathan Slonin, an insider at Pacira BioSciences (NASDAQ:PCRX), sold 3,261 shares of the company's stock on March 17th at an average price of $22.82, totaling approximately $74,416. This transaction reduced his stake by 1.44%. The sale occurred after Pacira BioSciences missed its quarterly earnings and revenue estimates, although revenue did increase year-over-year.
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905
Mark Froimson, a director at Pacira BioSciences Inc. (NASDAQ:PCRX), sold 500 shares of the company's common stock for $10,905 on March 17, 2026. This insider sale occurred shortly after Pacira BioSciences reported Q4 2025 earnings that missed analyst expectations for both EPS and revenue, and amid an ongoing dispute with activist investor DOMA Perpetual Capital Management LLC. Despite the sale, Froimson still directly owns 20,136 shares, and InvestingPro analysis suggests the stock is currently undervalued.
Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold 3,261 shares of common stock at $22.82 per share on March 17, 2026, as reported in an SEC Form 4 filing. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance. Following the sale, Slonin directly retains 223,640.175 shares of Pacira common stock.
Pacira BioSciences (PCRX) director sells 500 common shares in open market
Pacira BioSciences director Mark Froimson sold 500 shares of common stock at $21.81 per share in an open-market transaction on March 17, 2026. Following this sale, Froimson directly holds 20,136 shares of PCRX. The SEC Form 4 filing indicates that this was a relatively small sale compared to his remaining ownership.
Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant
Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. This grant was at no cash cost and increases his direct holdings to 31,065 common shares equivalents. The units are service-based compensation, vesting on June 11, 2026, provided he remains in continuous service with Pacira through that date.
PCRX (NASDAQ: PCRX) insider sale notice lists 3 share lots
Pacira BioSciences, Inc. (NASDAQ: PCRX) has filed a Form 144, indicating an insider's intent to sell common stock. The filing details three previously acquired share lots: 209 shares from an ESPP in 2021, 2,000 shares from stock option exercise in 2022, and 1,052 shares from restricted stock vesting in 2022. Fidelity Brokerage Services LLC is identified as the broker for the proposed sale, which does not confirm a completed transaction but rather the intent to sell.
[144] Pacira BioSciences, Inc. SEC Filing
This article details a Form 144 SEC filing by Pacira BioSciences, Inc. (PCRX) on March 17, 2026. The filing indicates a proposed sale of 500 shares of common stock by an individual, acquired through restricted stock vesting from the issuer on June 3, 2022, with an aggregate market value of $10,905.10. The filing was submitted by Fidelity Brokerage Services LLC to be transacted on NASDAQ.
Pacira BioSciences (NASDAQ:PCRX) Shares Down 4.7% - Time to Sell?
Shares of Pacira BioSciences (NASDAQ:PCRX) fell 4.7% on Tuesday, trading at $21.62 with significantly reduced volume. This drop followed the company missing quarterly earnings expectations, reporting EPS of $0.57 against a consensus of $0.85 and revenue of $196.87M, below analyst estimates. Analyst ratings are mixed with a consensus "Hold" and a price target of $30.75, while an SVP recently sold shares, indicating potential shifts in sentiment.
Radcliffe Capital Management L.P. Takes $1.23 Million Position in Pacira BioSciences, Inc. $PCRX
Radcliffe Capital Management L.P. has initiated a new position of 47,589 shares in Pacira BioSciences, Inc. (NASDAQ:PCRX), valued at approximately $1.23 million, representing 0.11% ownership. This move comes as other institutional investors have also adjusted their holdings in the company. Pacira BioSciences recently missed its quarterly earnings and revenue estimates, resulting in a "Hold" consensus rating from analysts with an average price target of $30.75.
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Pacira BioSciences, Inc. (Nasdaq: PCRX) has reaffirmed its commitment to shareholder value creation after DOMA Perpetual Capital Management LLC nominated three director candidates for the 2026 Annual Meeting. The company highlighted significant progress against its 5x30 strategy, including treating 2.5 million patients in 2025, increasing EXPAREL® volume growth, strengthening intellectual property, achieving record gross margins, and advancing clinical programs. Pacira also emphasized its disciplined capital allocation strategy and ongoing engagement with shareholders.
PCRX - Pacira Biosciences Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Pacira Biosciences (PCRX), a pharmaceutical company focused on non-opioid pain therapies. The company's news includes developments on its products EXPAREL, ZILRETTA, and iovera°, its gene therapy candidate PCRX-201, commercial partnerships, clinical data, manufacturing updates, and financial results. Recent news highlights shareholder value commitment, inducement grants, conference participation, and studies on its products' effectiveness.
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Pacira BioSciences (Nasdaq: PCRX) reaffirmed its commitment to shareholder value creation in response to DOMA Perpetual Capital Management LLC's nomination of three director candidates. The company highlighted significant progress on its "5x30 strategy," including increased patient reach, EXPAREL® volume growth, strengthened intellectual property, and record gross margins. Pacira's Board and management emphasized their ongoing evaluation and execution of growth and value creation strategies, advising shareholders that no action is required at this time regarding the director nominations.
[DFAN14A] Pacira BioSciences, Inc. SEC Filing
DOMA Perpetual Capital Management LLC, holding a 7.3% stake in Pacira BioSciences, Inc. (NASDAQ: PCRX), has nominated three director candidates to Pacira's board. DOMA is urging the removal of CEO Frank Lee, advocating for an interim CEO, and pushing for a formal sale process of the company, citing years of underperformance, governance issues, and lavish executive compensation. The firm plans to file a preliminary proxy statement and a WHITE universal proxy card to solicit votes for its nominees at the 2026 annual meeting.
Activist hedge fund pushes Pacira BioSciences to sell itself
An activist hedge fund is pressuring Pacira BioSciences to sell itself, citing wasteful spending by the company's board. The hedge fund has met with company leaders multiple times and a shareholder vote is anticipated as the dispute escalates.
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
DOMA Perpetual Capital Management LLC, owning 7.3% of Pacira BioSciences, Inc., has nominated three director candidates—Christopher Dennis, Oliver Benton Curtis III, and Eric de Armas—to Pacira's Board. DOMA asserts that Pacira's stock has underperformed significantly under current leadership, citing missed earnings, increased expenses, and compensation issues. DOMA believes a new board is crucial to review strategy, halt further acquisitions, and potentially sell the company to maximize shareholder value and accelerate EXPAREL's distribution.
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Pacira BioSciences (Nasdaq: PCRX) has reaffirmed its commitment to shareholder value creation in response to DOMA Perpetual Capital Management LLC's nomination of three director candidates. The company highlighted significant progress in its 5x30 strategy, including treating 2.5 million patients in 2025, increasing EXPAREL® volume growth by 6.2%, achieving record gross margins of 79% (GAAP) and 81% (non-GAAP), advancing two Phase 2 clinical programs, and expanding commercial reach. Pacira's Board and management assert their dedication to accelerating growth and executing a long-term plan to deliver value for all shareholders.
Pacira BioSciences responds to DOMA director nominations
Pacira BioSciences, Inc. confirmed that DOMA Perpetual Capital Management LLC has nominated three director candidates for election to its board in 2026. Pacira stated that DOMA has not offered new insights beyond what the company is already evaluating, highlighting its 2025 performance including 2.5 million patients treated and increased EXPAREL volume growth. This follows a recent report of Q4 2025 earnings shortfalls and DOMA's advocacy for removing CEO Frank Lee.
Pacira BioSciences (NASDAQ:PCRX) Downgraded to "Strong Sell" Rating by Zacks Research
Zacks Research downgraded Pacira BioSciences (NASDAQ:PCRX) from a "hold" to a "strong sell" rating. This downgrade follows the company missing quarterly EPS and revenue expectations. Analyst opinions on PCRX are mixed, with a consensus "Hold" rating and a target price of $30.75 against a current trading price around $22.44.
Liquidity Mapping Around (PCRX) Price Events
This article provides a liquidity mapping analysis for Pacira Biosciences Inc. (NASDAQ: PCRX) based on AI-generated signals. It highlights a strong near-term sentiment with a neutral mid and long-term outlook, identifying an exceptional risk-reward setup. The analysis offers specific trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Pacira BioSciences, Inc. (NASDAQ:PCRX) and its officers/directors. The firm is encouraging shareholders who purchased Pacira securities before August 2, 2023, and still hold them, to come forward and assist with the investigation. The firm operates on a contingency fee basis, meaning there is no cost to investors unless a recovery is successful.
Pacira BioSciences, Inc. $PCRX Shares Purchased by American Century Companies Inc.
American Century Companies Inc. significantly increased its stake in Pacira BioSciences Inc. (NASDAQ: PCRX) by 16.6% in the third quarter, holding over 1.3 million shares valued at approximately $35.5 million. This comes despite Pacira BioSciences missing quarterly earnings estimates, reporting $0.57 EPS against an expected $0.85, and revenue of $196.9 million against an estimated $201.9 million. Insider sales have also been noted, with SVP Lauren Riker and CFO Shawn Cross selling shares totaling over $744,000 in the last three months.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences, Inc. announced inducement grants to three new employees on March 3, 2026, under its Amended and Restated 2014 Inducement Plan. These awards were approved by the People & Compensation Committee of the Board of Directors without stockholder approval, in accordance with Nasdaq Listing Rule 5635(c)(4), as a material inducement for their employment. The company is a leader in non-opioid pain therapies.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences, Inc. announced inducement awards granted on March 3, 2026, to three new employees. These awards, consisting of stock options and restricted stock units, were approved by the People & Compensation Committee of the Board of Directors under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The awards are subject to vesting schedules and continued employment with Pacira.
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira Biosciences announced inducement grants issued under Nasdaq Listing Rule 5635(C)(4). This report is a brief notification regarding the company's compliance with specific Nasdaq regulations for stock inducements. The information was provided by Refinitiv and Reuters.
Pacira BioSciences grants inducement stock options, RSUs | PCRX Stock News
Pacira BioSciences announced the granting of inducement equity awards to three new employees on March 3, 2026, under its Amended and Restated 2014 Inducement Plan. One employee received options for 2,400 shares with a 10-year term and a four-year vesting schedule, and an exercise price of $22.10. Three employees collectively received 5,500 Restricted Stock Units (RSUs) that will vest annually over four years, starting March 1, 2027.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by Pacira BioSciences, Inc. (NASDAQ:PCRX). The firm is encouraging shareholders who purchased Pacira securities before August 2, 2023, and still hold them, to join the investigation. The goal is to determine if Pacira and its officers/directors engaged in any misconduct.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced its participation in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 2:30 PM ET in Miami. The company, a leader in non-opioid pain therapies, will have live audio of the event accessible on its investor relations website, with a replay available for two weeks. Pacira focuses on innovative treatments like EXPAREL, ZILRETTA, and iovera, and is advancing clinical-stage assets for musculoskeletal pain, including PCRX-201 for osteoarthritis of the knee.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced its participation in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 2:30 PM ET in Miami. The event's live audio will be accessible via the company's investor relations website, with a replay available for two weeks. Pacira focuses on developing innovative non-opioid pain therapies, including commercially available EXPAREL, ZILRETTA, and ioveraº, and is advancing a pipeline of clinical-stage assets.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced its participation in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 2:30 PM ET in Miami. The company, known for its non-opioid pain therapies, will have the event's audio accessible via its investor website, with a replay available for two weeks. Pacira focuses on developing and commercializing innovative non-opioid pain treatments, including EXPAREL, ZILRETTA, and ioveraº, and is advancing a pipeline of clinical-stage assets.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) held its Q4 2025 earnings call, reporting revenues of $726 million for 2025 and exceeding earnings expectations for the year despite a Q4 EPS miss. The company highlighted significant progress on its "five-by-30" strategy, including expanded EXPAREL coverage, new partnerships with LG Chem and J&J MedTech, and advancements in its pipeline, particularly PCRX-201. Pacira also provided financial guidance for 2026, projecting total revenue between $745 million and $770 million, and discussed its capital allocation strategy, which includes share repurchases and investments in its R&D pipeline.
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX
Vanguard Group Inc. reduced its stake in Pacira BioSciences, Inc. by 3.9% in the third quarter, now owning 5,197,567 shares valued at approximately $133.94 million. This move comes as Pacira BioSciences missed recent quarterly earnings and revenue expectations. Analysts generally have a "Hold" rating on PCRX, with a consensus price target of $30.75.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
Pacira BioSciences, Inc. announced its participation in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026. The event will take place in Miami at 2:30 PM ET, with a live audio webcast available on the company's investor relations website. Pacira is a leader in non-opioid pain therapies, offering products like EXPAREL, ZILRETTA, and iovera, and is advancing a pipeline of clinical-stage assets.
PCRX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides an in-depth financial analysis of Pacira Biosciences Inc. (PCRX) for fiscal year 2025, covering its income statement, balance sheet, and cash flow. Key metrics include revenue of $726.4M, net income of $7.0M, and an EBITDA of $110.2M. The company's financial health is rated as moderate (57/100) with a strong Piotroski F-Score but an Altman Z-Score indicating elevated financial distress risk.
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
Pacira BioSciences presented real-world evidence from its Innovations in Genicular Outcomes Registry (IGOR) at the American Academy of Orthopedic Surgeons 2026 Annual Meeting. Two studies highlighted the clinical effectiveness of EXPAREL for total knee arthroplasty, showing improved pain, opioid use, function, and shorter hospital stays compared to conventional anesthetics. Another study demonstrated that cryoneurolysis with ioveraº provided longer-term pain and function improvement for up to 12 months in knee osteoarthritis patients, outperforming typical intra-articular agents.
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
Pacira BioSciences announced the presentation of two real-world studies from its Innovations in Genicular Outcomes Registry (IGOR). These studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and demonstrate long-term pain management with iovera for patients suffering from osteoarthritis of the knee. The news was provided by GlobeNewswire and is relevant for investors following NASDAQ:PCRX.
